Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) CEO Nello Mainolfi sold 30,000 shares of the business's stock in a transaction that occurred on Wednesday, April 29th. The stock was sold at an average price of $81.18, for a total value of $2,435,400.00. Following the sale, the chief executive officer owned 666,195 shares of the company's stock, valued at $54,081,710.10. The trade was a 4.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Nello Mainolfi also recently made the following trade(s):
- On Wednesday, February 25th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.26, for a total value of $2,707,800.00.
Kymera Therapeutics Stock Performance
Shares of KYMR opened at $81.51 on Thursday. Kymera Therapeutics, Inc. has a one year low of $28.06 and a one year high of $103.00. The stock has a market capitalization of $6.65 billion, a price-to-earnings ratio of -22.15 and a beta of 2.28. The stock has a 50 day moving average price of $84.63 and a 200 day moving average price of $76.20.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm had revenue of $2.87 million for the quarter, compared to analysts' expectations of $14.80 million. During the same quarter in the previous year, the firm posted ($0.88) earnings per share. The firm's revenue for the quarter was down 60.8% compared to the same quarter last year. On average, analysts predict that Kymera Therapeutics, Inc. will post -3.65 earnings per share for the current year.
Hedge Funds Weigh In On Kymera Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC boosted its stake in Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock worth $42,000 after buying an additional 424 shares during the last quarter. Larson Financial Group LLC lifted its stake in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company's stock valued at $44,000 after purchasing an additional 349 shares during the last quarter. Osaic Holdings Inc. lifted its stake in shares of Kymera Therapeutics by 18,050.0% in the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock valued at $48,000 after purchasing an additional 1,083 shares during the last quarter. Bessemer Group Inc. lifted its stake in shares of Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company's stock valued at $53,000 after purchasing an additional 815 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Kymera Therapeutics in the 4th quarter valued at $63,000.
Analyst Upgrades and Downgrades
Several analysts recently commented on KYMR shares. BTIG Research dropped their price target on Kymera Therapeutics from $138.00 to $134.00 and set a "buy" rating for the company in a research report on Thursday, February 26th. Stephens boosted their price objective on Kymera Therapeutics from $95.00 to $100.00 and gave the stock an "overweight" rating in a research note on Monday, March 2nd. UBS Group boosted their price objective on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a "buy" rating in a research note on Tuesday, March 3rd. Jefferies Financial Group began coverage on Kymera Therapeutics in a research note on Monday, March 16th. They set a "buy" rating and a $110.00 price objective on the stock. Finally, Royal Bank Of Canada reissued an "outperform" rating and set a $108.00 price objective on shares of Kymera Therapeutics in a research note on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $118.90.
Check Out Our Latest Report on Kymera Therapeutics
Kymera Therapeutics Company Profile
(
Get Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
